First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia

被引：6
|
作者：
Argyropoulos, Kimon V. [1 ]
Lia, M. [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Program Immunol, 408 East 69th St, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, 1275 York Ave, New York, NY 10065 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 05期
关键词：
Waldenstrom macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors; B-CELL-RECEPTOR; ATRIAL-FIBRILLATION; GENE REARRANGEMENT; SOMATIC MUTATION; CLINICAL-TRIAL; IBRUTINIB USE; ACTIVATION; BTK; RESISTANCE; MYD88;
D O I：
10.1016/j.hoc.2018.05.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Waldenstrom macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this article.
引用
下载
收藏
页码：853 / +
页数：13
相关论文
共 50 条
  • [21] Educational Assimilation of First-Generation and Second-Generation Immigrants in Germany
    Thomas Gries
    Margarete Redlin
    Moonum Zehra
    Journal of International Migration and Integration, 2022, 23 : 815 - 845
  • [22] Next-Generation Bruton Tyrosine Kinase Inhibitors
    Stephens, Deborah M.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2937 - +
  • [23] First-generation tyrosine-kinase inhibitors: the role of combination therapy
    Guilhot, F.
    ONCOLOGIE, 2012, 14 (10-11) : 583 - 588
  • [24] Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy
    Kantarjian, Hagop M.
    Baccarani, Michele
    Jabbour, Elias
    Saglio, Giuseppe
    Cortes, Jorge E.
    CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1674 - 1683
  • [25] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
    Swords R.
    Alvarado Y.
    Cortes J.
    Giles F.J.
    Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
  • [26] Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
    Bhargava, Pankaj
    Robinson, Murray O.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 103 - 111
  • [27] Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors
    Bixby, Dale L.
    Talpaz, Moshe
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 : S95 - S106
  • [28] Second-generation tyrosine-kinase inhibitors: their role as a first-line treatment in 2012
    Rousselot, P.
    ONCOLOGIE, 2012, 14 (10-11) : 596 - 600
  • [29] Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
    Pankaj Bhargava
    Murray O. Robinson
    Current Oncology Reports, 2011, 13 : 103 - 111
  • [30] Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenstrom macroglobulinemia
    Buske, Christian
    LANCET HAEMATOLOGY, 2020, 7 (02): : E85 - E86
12345